

**AMENDMENTS TO THE CLAIMS**

**This listing of claims will replace all prior versions and listings of claims in the application:**

**LISTING OF CLAIMS:**

1-32 (Cancelled)

33: (previously presented) An expression vector,

which comprises: (a) a first coding region encoding PPIase having molecular chaperone activity, and

(b) a region having at least one restriction enzyme site in which a second coding region encoding a desired protein can be inserted.

34: (previously presented): The expression vector according to claim 33, wherein the first coding region is operatively linked to a promoter, and the restriction enzyme site is in the same reading frame as the first coding region, and is downstream of the first coding region.

35: (currently amended): The expression vector according to claim 33 or 34, which has a region being between a first coding region and a region having at least one restriction enzyme site in which a second coding region can be inserted, and is translated in the same reading frame to be a protease digestion site.

36: (currently amended): An expression vector, wherein a second coding region encoding a desired protein is inserted into the expression vector according to claim 33, 34 or 35.

37: (currently amended): The expression vector according to claim 33, 34, 35 or 36, wherein the PPIase having molecular chaperone activity is FKBP-type PPIase.

38. (currently amended): The expression vector according to claim 33, ~~34, 35 or 36~~,  
wherein the PPIase having molecular chaperone activity is cyclophilin-type  
PPIase.

39. (currently amended): The expression vector according to claim 33, ~~34, 35 or 36~~,  
wherein the PPIase having molecular chaperone activity is parvulin-type  
PPIase.

40. (previously presented): The expression vector according to claim 37,  
wherein the FKBP-type PPIase is archaeobacterial FKBP-type PPIase.

41. (previously presented) The expression vector according to claim 40,  
wherein the archaeobacterial FKBP-type PPIase is short type FKBP-type  
PPIase.

42. (currently amended): The expression vector according to claim 33, ~~34, 35, 36, 37,~~  
~~38 or 39~~,  
wherein the PPIase having molecular chaperone activity comprises an IF domain  
and/or a C-terminal domain of archaeobacterial FKBP-type PPIase.

43. (previously presented): The expression vector according to claim 37,  
wherein the FKBP-type PPIase is trigger factor-type PPIase.

44. (currently amended): The expression vector according to claim 33, ~~34, 35, 36, 37,~~  
~~38 or 39~~,  
wherein the PPIase having molecular chaperone activity comprises a N-terminal  
domain and/or a C-terminal domain of trigger factor-type PPIase.

45. (previously presented): The expression vector according to claim 37,  
wherein the FKBP-type PPIase is FkpA-type PPIase.

46. (currently amended): The expression vector according to claim 33, ~~34, 35, 36, 37,~~  
~~38 or 39,~~

wherein the PPIase having molecular chaperone activity comprises a N-terminal domain of FkpA-type PPIase.

47. (previously presented): The expression vector according to claim 37,  
wherein the FKBP-type PPIase is FKBP52-type PPIase.

48. (currently amended): The expression vector according to claim 33, ~~34, 35, 36, 37,~~  
~~38 or 39,~~

wherein the PPIase having molecular chaperone activity comprises a C-terminal domain of FKBP52-type PPIase.

49. (previously presented): The expression vector according to claim 38,  
wherein the cyclophilin-type PPIase is CyP40-type PPIase.

50. (currently amended): The expression vector according to claim 33, ~~34, 35, 36, 37,~~  
~~38 or 39,~~

wherein the PPIase having molecular chaperone activity comprises a C-terminal domain of CyP40-type PPIase.

51. (previously presented): The expression vector according to claim 39,  
wherein the parvulin-type PPIase is SurA-type PPIase.

52. (currently amended): The expression vector according to claim 33, ~~34, 35, 36, 37,~~  
~~38 or 39,~~

wherein the PPIase having molecular chaperone activity comprises a N-terminal domain of SurA-type PPIase.

53. (currently amended): The expression vector according to claim 36, ~~37, 38, 39, 40,~~  
~~41, 42, 43, 44, 45, 46, 47, 48, 49, 50, 51 or 52,~~

wherein the second coding region has a nucleotide sequence encoding a monoclonal antibody.

54. (currently amended): The expression vector according to claim ~~36, 37, 38, 39, 40, 41, 42, 43, 44, 45, 46, 47, 48, 49, 50, 51 or 52,~~

wherein the second coding region has a nucleotide sequence encoding a membrane protein.

55. (currently amended): A host,

which contains the expression vector according to claim ~~33, 34, 35, 36, 37, 38, 39, 40, 41, 42, 43, 44, 45, 46, 47, 48, 49, 50, 51, 52, 53 or 54.~~

56. (previously presented): The host according to claim 55,

which is *Escherichia coli*.

57. (previously presented) A fused protein,

which comprises PPIase having molecular chaperone activity and a desired protein.

58. (previously presented): The fused protein according to claim 57,

which comprises a protease digestion site between PPIase having molecular chaperone activity and a desired protein.

59. (currently amended): A process for producing a fused protein comprising PPIase having molecular chaperone activity and a desired protein,

which comprises making the expression vector according to claim ~~36, 37, 38, 39, 40, 41, 42, 43, 44, 45, 46, 47, 48, 49, 50, 51, 52, 53 or 54,~~ express the fused protein.

60. (previously presented): The process for producing a fused protein according to claim 59,

which comprises culturing the host containing the expression vector under condition of expression of the expression vector, and making express the fused protein in a cytoplasm.

61. (previously presented): The process for producing a fused protein according to claim 59,

which comprises providing a region being transcribed and translated to be a signal sequence at a 5' terminus of a first coding region or a 5' terminus of a second coding region of the expression vector, and culturing a host containing the expression vector under condition of expression of the expression vector to express the fused protein in a periplasm or a medium.

62. (previously presented): The process for producing a fused protein according to claim 59,

which comprises making the expression vector express the fused protein in a cell-free translation system.

63. (currently amended): The process for producing a fused protein according to claim 59, ~~60, 61 or 62~~,

wherein the fused protein is adsorbed on a carrier harboring macrolide, cyclosporin, juglone or its analogous compound inhibiting PPIase activity, and then the carrier is recovered and the fused protein is recovered from the carrier.

64. (currently amended): A process for producing a desired protein, which comprises digesting the fused protein comprising a protease digestion site obtained by the process according to claim 59, ~~60, 61, 62 or 63~~, with a protease digesting a protease digestion site.